A recent study conducted on BRAF-mutant melanoma xenografts [64] demonstrated that the combination of the BRAFi PLX4720 and bevacizumab was more effective than each single agent in inhibiting tumor growth and metastasis and also delayed the onset of acquired resistance. This evidence concerns the gene BRAF and neoplasm.